Beat­ing out mar­ket lead­ers in PhII, an­tibi­ot­ic-mak­er Al­le­cra read­ies for Phase III tri­als

Eu­ro­pean biotech Al­le­cra an­nounced good news from the front­lines of its fight against mul­tidrug-re­sis­tant gram-neg­a­tive bac­te­ria – some of the most dan­ger­ous su­per­bugs around – af­ter wrap­ping up a Phase II study of its in­ves­ti­ga­tion­al an­tibi­ot­ic.

The com­pa­ny’s lead an­tibi­ot­ic can­di­date, an ex­tend­ed spec­trum β-lac­ta­mase in­hibitor known as AAI101, met all of the study’s ob­jec­tives, prep­ping Al­le­cra to take the drug in­to Phase III.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.